文献速递冠心病心力衰竭与心肌病

半乳糖凝集素-3水平与心肌梗死后结局:一项基于人群的研究

Galectin-3 Levels and Outcomes After Myocardial Infarction: A Population-Based Study.
PubMed 文献 · J Am Coll Cardiol · 2019-01-01

该研究在明尼苏达州奥姆斯特德县前瞻性纳入2002至2012年首发心肌梗死患者1342例,测量梗死后半乳糖凝集素-3(Gal-3)水平并随访心力衰竭与死亡。中位随访5.4年,Gal-3最高三分位组较最低三分位组死亡风险增加2.4倍、心衰风险增加2.3倍,且独立于可溶性ST2。

要点

  • Gal-3升高与心梗后死亡和心衰风险独立相关,呈剂量效应。
  • Gal-3最高三分位组死亡风险增2.4倍,心衰风险增2.3倍。
  • Gal-3或可用于心梗后风险分层,辅助识别高危患者。

核心结论

  • Gal-3是心肌梗死后死亡和心力衰竭的独立预测因子。
  • 研究提示测量Gal-3水平可用于心梗后风险分层。

研究设计与样本

  • 基于人群的前瞻性首发心肌梗死队列研究,2002至2012年于明尼苏达州奥姆斯特德县纳入1342例患者。
  • 患者平均年龄67.1岁,男性占61.3%,非ST段抬高型心肌梗死占78.8%;心肌梗死时测量Gal-3水平,随访心力衰竭和死亡。

主要发现

  • 平均随访5.4年,484例(36.1%)死亡,368例(27.4%)发生心力衰竭。
  • 校正年龄、性别、合并症和肌钙蛋白后,Gal-3第二和第三三分位组较第一三分位组死亡风险分别增加1.3倍(95%CI:0.9倍至1.7倍)和2.4倍(95%CI:1.8倍至3.2倍),趋势P<0.001。
  • Gal-3第二和第三三分位组心衰风险分别增加1.4倍(95%CI:1.0至2.0)和2.3倍(95%CI:1.6至3.2),趋势P<0.001。
  • 进一步校正可溶性ST2后,Gal-3仍与死亡和心衰风险增加相关。
  • 心衰风险增加不因心衰类型而异,且独立于再发心肌梗死。

临床怎么用

  • 对心肌梗死后患者,可考虑检测Gal-3水平以辅助风险分层,识别死亡和心衰高危人群。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Galectin-3 (Gal-3) is implicated in cardiac fibrosis, but its association with adverse outcomes after myocardial infarction (MI) is unknown. OBJECTIVES: The purpose of this study was to examine the prognostic value of Gal-3 in a community cohort of incident MI. METHODS: A population-based incidence MI cohort was prospectively assembled in Olmsted County, Minnesota, between 2002 and 2012. Gal-3 levels were measured at the time of MI. Patients were followed for heart failure (HF) and death. RESULTS: A total of 1,342 patients were enrolled (mean age 67.1 years; 61.3% male; 78.8% non-ST-segment elevation MI). Patients with elevated Gal-3 were older and had more comorbidities. Over a mean follow-up of 5.4 years, 484 patients (36.1%) died and 368 (27.4%) developed HF. After adjustment for age, sex, comorbidities, and troponin, patients with Gal-3 values in tertiles 2 and 3 had a 1.3-fold (95% confidence interval [CI]: 0.9-fold to 1.7-fold) and a 2.4-fold (95% CI: 1.8-fold to 3.2-fold) increased risk of death, respectively (ptrend < 0.001) compared with patients with Gal-3 values in tertile 1. Patients with Gal-3 values in tertiles 2 and 3 had a higher risk of HF with hazard ratios of 1.4 (95% CI: 1.0 to 2.0) and 2.3 (95% CI: 1.6 to 3.2), respectively (ptrend < 0.001). With further adjustment for soluble suppression of tumorigenicity-2, elevated Gal-3 remained associated with increased risk of death and HF. The increased risk of HF did not differ by HF type and was independent of the occurrence of recurrent MI. CONCLUSIONS: Gal-3 is an independent predictor of mortality and HF post-MI. These findings suggest a role for measuring Gal-3 levels for risk stratification post-MI.

来源:J Am Coll Cardiol,查看原文。版权归原作者所有。

引用

  1. Asleh R, Enriquez-Sarano M, Jaffe AS, et al. Galectin-3 Levels and Outcomes After Myocardial Infarction: A Population-Based Study. J Am Coll Cardiol. 2019. PMID: 31072572. doi:10.1016/j.jacc.2019.02.046

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。